Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are adult males diagnosed with metastatic castration-resistant prostate cancer (a form of prostate cancer that has spread and no longer responds to hormone-lowering treatments), where their treating doctor has decided to start them on a specific radioactive drug therapy called lutetium-177 PSMA (also known as lutetium vipivotide tetraxetan)
- People who are 18 years of age or older at the time of joining the trial
- People who have provided written consent to take part before any information is collected about them
- People who are willing to complete quality-of-life questionnaires for up to one year after starting treatment
Who may not be able to join:
- People who are already taking part in another clinical trial testing a new treatment at the same time, or who are already enrolled in another Novartis-sponsored observational study involving the same lutetium drug
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Functional Assessment of Cancer Therapy - Prostate (FACT-P); Change from baseline in FACT-P; Functional Assessment of Cancer Therapy-Radionuclid Therapy (FACT-RNT); Change from baseline in FACT-RNT; Brief Pain Inventory-Short Form (BPI-SF); Change from baseline in BPI-SF; Radiographic progression; Clinical progression; Time to prostate-specific antigen (PSA) progression; Prostate-specific antigen (PSA) 30/50/90; Progression-free survival (PFS); Progression-free survival 2 (PFS2); Overall Survival (OS); Time to initiation of pain medication
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.